Patents by Inventor Paul John Beswick

Paul John Beswick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20230181535
    Abstract: The present invention relates to a novel class of compounds and to compositions comprising the same as well as their used as medicaments in the treatment of cancer.
    Type: Application
    Filed: May 13, 2021
    Publication date: June 15, 2023
    Inventors: Angélica FIGUEROA CONDE-VALVÍS, Alba CASAS PAIS, Andrea RODRÍGUEZ ALONSO, Paul John BESWICK
  • Bicyclic peptide ligands and uses thereof
    Patent number: 11241473
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: September 2, 2020
    Date of Patent: February 8, 2022
    Assignee: BicycleTx Limited
    Inventors: Paul John Beswick, Gabriela Ivanova-Berndt, Gemma Elizabeth Mudd, Silvia Pavan, Michael Skynner, Daniel Paul Teufel, Katerine Van Rietschoten
  • NOVEL LINKERS
    Publication number: 20220031858
    Abstract: The invention relates to novel linkers which comprise two or three basic, acidic or hydrophobic natural or non-natural amino acids. The invention also relates to drug conjugates comprising said linkers, to pharmaceutical compositions comprising said drug conjugates and to the use of said drug conjugates in preventing, suppressing or treating cancer.
    Type: Application
    Filed: August 3, 2021
    Publication date: February 3, 2022
    Inventors: Kevin MCDONNELL, Gemma MUDD, Paul John Beswick
  • BICYCLIC PEPTIDE LIGANDS AND USES THEREOF
    Publication number: 20210046145
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: September 2, 2020
    Publication date: February 18, 2021
    Inventors: Paul John Beswick, Gabriela Ivanova-Berndt, Gemma Elizabeth Mudd, Silvia Pavan, Michael Skynner, Daniel Paul Teufel, Katerine Van Rietschoten
  • Bicyclic peptide ligands and uses thereof
    Patent number: 10857196
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: December 8, 2020
    Assignee: BicycleTx Limited
    Inventors: Paul John Beswick, Gabriela Ivanova-Berndt, Gemma Elizabeth Mudd, Silvia Pavan, Michael Skynner, Daniel Paul Teufel, Katerine Van Rietschoten
  • BICYCLIC PEPTIDE LIGANDS AND USES THEREOF
    Publication number: 20180311300
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: April 27, 2018
    Publication date: November 1, 2018
    Inventors: Paul John Beswick, Gabriela Ivanova-Berndt, Gemma Elizabeth Mudd, Silvia Pavan, Michael Skynner, Daniel Paul Teufel, Katerine Van Rietschoten
  • 3-pyridylcarbonyl-piperazinylsulfonyl derivatives
    Patent number: 8536183
    Abstract: The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: September 17, 2013
    Assignee: Convergence Pharmaceuticals Limited
    Inventors: Paul John Beswick, Alister Campbell, Andrew Cridland, Robert James Gleave, Jag Paul Heer, Neville Hubert Nicholson, Lee William Page, Sadie Vile
  • Piperazine derivatives used as CAV2.2 calcium channel modulators
    Patent number: 8530478
    Abstract: The present invention relates to novel piperazine derivatives (I); to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: September 10, 2013
    Assignee: Convergence Pharmaceuticals Limited
    Inventors: Paul John Beswick, Alister Campbell, Andrew Peter Cridland, Robert James Gleave, Jag Paul Heer, Neville Hubert Nicholson, Lee William Page, Sadie Vile
  • NOVEL COMPOUNDS
    Publication number: 20130109711
    Abstract: The invention relates to novel spirocyclic derivatives with affinity for Cav2.2 calcium channels and which are capable of interfering with Cav2.2 calcium channels; to processes for their preparation; to pharmaceutical compositions containing them; and to the use of such compounds in therapy for the treatment of pain.
    Type: Application
    Filed: May 10, 2011
    Publication date: May 2, 2013
    Inventors: Robert James Gleave, Shuji Hachisu, Lee William Page, Paul John Beswick
  • 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES
    Publication number: 20120302746
    Abstract: The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.
    Type: Application
    Filed: August 7, 2012
    Publication date: November 29, 2012
    Inventors: Paul John Beswick, Alister Campbell, Andrew Cridland, Robert James Gleave, Jag Paul Heer, Neville Hubert Nicholson, Lee William Page, Sadie Vile
  • 3-pyridylcarbonyl-piperazinylsulfonyl derivatives
    Patent number: 8288388
    Abstract: The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.
    Type: Grant
    Filed: July 15, 2009
    Date of Patent: October 16, 2012
    Assignee: Convergence Pharmaceuticals Limited
    Inventors: Paul John Beswick, Alister Campbell, Andrew Cridland, Robert James Gleave, Jag Paul Heer, Neville Hubert Nicholson, Lee William Page, Sadie Vile
  • PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS
    Publication number: 20110130379
    Abstract: The present invention relates to novel piperazine derivatives (I); to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.
    Type: Application
    Filed: July 15, 2009
    Publication date: June 2, 2011
    Applicant: CONVERGENCE PHARMACEUTICALS LIMITED
    Inventors: Paul John Beswick, Alister Campbell, Andrew Peter Cridland, Robert James Gleave, Jag Paul Heer, Neville Hubert Nicholson, Lee William Page, Sadie Vile
  • Imidazolidine carboxamide derivatives as P2X7 modulators
    Patent number: 7932282
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: The compounds or salts modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor (P2X7 receptor antagonists). The invention also provides the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment or prevention of disorders/diseases mediated by the P2X7 receptor, for example pain, inflammation or a neurodegenerative disease, in particular pain such as inflammatory pain, neuropathic pain or visceral pain.
    Type: Grant
    Filed: April 2, 2008
    Date of Patent: April 26, 2011
    Assignee: Glaxo Group Limited
    Inventors: Paul John Beswick, David Kenneth Dean, Robert James Gleave, Andrew Peter Moses, Daryl Simon Walter
  • Pyrazole Derivatives as P2X7 Modulators
    Publication number: 20110046137
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: The pyrazole derivatives of formula (I) or salts thereof modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor (P2X7 receptor antagonists). The invention also relates to the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment or prevention of disorders/diseases mediated by the P2X7 receptor, for example pain, inflammation or a neurodegenerative disease.
    Type: Application
    Filed: May 8, 2008
    Publication date: February 24, 2011
    Inventors: Paul John Beswick, Laura Jane Chambers, Iain Patrick Chessell, David John Davies, Emmanuel Hubert Demont, Robert James Gleave, David George Hubert Livermore, Pamela Joan Theobald, Mythily Vimal, Daryl Simon Walter
  • Piperidinone Carboxamide Derivatives as P2X7 Modulators
    Publication number: 20100168171
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: The compounds or salts modulate P2X7 receptor function and are capable of interfering with the effects of ATP at the P2X7 receptor. The invention also provides the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment or prevention of disorders mediated by the P2X7 receptor, for example pain, inflammation or a neurodegenerative disease, in particular pain such as inflammatory pain, neuropathic pain or visceral pain.
    Type: Application
    Filed: March 20, 2008
    Publication date: July 1, 2010
    Inventors: Paul John Beswick, Robert James Gleave, Jon Graham Anthony Steadman, Daryl Simon Walter
  • Oxazolidine and Morpholine Carboxamide Derivatives as P2X7 Modulators
    Publication number: 20100144727
    Abstract: The present invention relates to a compound of formula (I): The compounds modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of such compounds, or pharmaceutical compositions thereof, in the treatment or prevention of disorders mediated by the P2X7 receptor, for example pain, inflammation or a neurodegenerative disease, in particular pain such as inflammatory pain, neuropathic pain or visceral pain.
    Type: Application
    Filed: March 20, 2008
    Publication date: June 10, 2010
    Inventors: Paul John Beswick, Daryl Simon Walter
  • Imidazolidine Carboxamide Derivatives as P2X7 Modulators
    Publication number: 20100075968
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: The compounds or salts modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor (P2X7 receptor antagonists). The invention also provides the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment or prevention of disorders/diseases mediated by the P2X7 receptor, for example pain, inflammation or a neurodegenerative disease, in particular pain such as inflammatory pain, neuropathic pain or visceral pain.
    Type: Application
    Filed: April 2, 2008
    Publication date: March 25, 2010
    Inventors: Paul John Beswick, David Kenneth Dean, Robert James Gleave, Andrew Peter Moses, Daryl Simon Walter
  • Pyrazole Derivatives as P2X7 Modulators
    Publication number: 20100056595
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 represents C1-6 alkyl or C3-6 cycloalkyl, either of which is optionally substituted with 1, 2 or 3 halogen atoms; and R2 represents hydrogen, halogen, C1-6 alkyl or C3-6 cycloalkyl; and either of said C1-6 alkyl or C3-6 cycloalkyl is optionally substituted with 1, 2 or 3 halogen atoms. The pyrazole compounds of formula (I) or salts thereof modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor (P2X7 receptor antagonists). The invention also relates to the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment or prevention of disorders/diseases mediated by the P2X7 receptor, for example pain, inflammation or a neurodegenerative disease.
    Type: Application
    Filed: April 10, 2008
    Publication date: March 4, 2010
    Applicant: Glaxo Group Limited
    Inventors: Paul John Beswick, David Kenneth Dean, Daryl Simon Walter
  • Novel Derivatives
    Publication number: 20100022555
    Abstract: The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.
    Type: Application
    Filed: July 15, 2009
    Publication date: January 28, 2010
    Inventors: Paul John Beswick, Alister Campbell, Andrew Cridland, Robert James Gleave, Jag Paul Heer, Neville Hubert Nicholson, Lee William Page, Sadie Vile
  • Novel Receptor Antagonists and Their Methods of Use
    Publication number: 20090197928
    Abstract: The present invention relates to novel isoxazole derivatives of formula (I) which bind to the P2X7 receptor and are capable of interfering with the effects of ATP at the P2X7 receptor: and the use of such compounds or pharmaceutical compositions thereof in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation and neurodegeneration.
    Type: Application
    Filed: June 5, 2007
    Publication date: August 6, 2009
    Inventors: Paul John Beswick, Daryl Simon Walter